Literature DB >> 27150963

Synthesis, Cytotoxic Activity on Leukemia Cell Lines and Quantitative Structure-Activity Relationships (QSAR) Studies of Morita-Baylis-Hillman Adducts.

Claudio G Lima-, Gláucia V Faheina-Martins, Caio C B Bomfim, Bruna B Dantas, Everton P Silva, Demetrius A M de Araújo, Edilson B A Filho, Mário L A A Vasconcellos1.   

Abstract

BACKGROUND: The Morita-Baylis-Hillman reaction is an organocatalyzed chemical transformation that allows access to small poly-functionalized molecules and has considerable synthetic potential and promising biological profiles. The Morita-Baylis-Hillman adducts (MBHA) are a new class of bioactive compounds and highlight its potentialities to the discovery of new cheaper and efficient drugs, e.g. as anti-Leishmania chagasi and Leishmania amazonensis, anti- Trypanosoma cruzi, anti-Plasmodium falciparum and Plasmodium berghei, lethal against Biomphalaria glabrata, antibacterial, antifungal, herbicide and others.
METHODS: The goal of this work is to describe the primary cytotoxic activities against strains of human leukemia HL-60 cell line for thirty-four Morita-Baylis- Hillman adducts (MBHA), followed by a Quantitative Structure-Activity Relationships study (QSAR).
RESULTS: The conventional or microwave-assisted syntheses of MBHA, derived from substituted aromatics or Isatin, were performed in good to excellent yields (70-100%) in short reaction times, using protocols recently developed by us. Isatin derivatives, MBHA 31 and 32, were the most active in this congener series of compounds, with IC50 values of 10.8 μM and 7.8 μM, respectively. The primary cytotoxic activities against chronic leukemia cells (K562) were also evaluated to these two most active compounds (MBHA 31 and 32), presenting IC50 values of 53 μM and 43 μM respectively. QSAR study was performed considering 3D, 2D and constitutional molecular descriptors. These were selected from Ordered Predictor Selection algorithm and submitted to Partial Least Squares Modeling.
CONCLUSION: We present an interesting investigation about cytotoxic activities on human leukemia cell line (HL-60) for 34 synthetic MBHA. In a good way we discovered that the most cytotoxic compounds (31-32, 10.8 μM and 7.8 μM respectively) were also prepared quantitatively (100% yields) in a short reaction time using microwave irradiation. We demonstrate that 31 and 32 induced apoptosis and not necrosis in HL-60 cells, observed by externalization of PS and increase Anexin-V positive cells. Quantitative Structure-Activity Relationships considering 3D, 2D and constitutional descriptors provided a robust and predictive PLS model, in accordance with SAR observations.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27150963     DOI: 10.2174/1573406412666160506150924

Source DB:  PubMed          Journal:  Med Chem        ISSN: 1573-4064            Impact factor:   2.745


  3 in total

1.  Synthesis, anti-proliferative activity, theoretical and 1H NMR experimental studies of Morita-Baylis-Hillman adducts from isatin derivatives.

Authors:  Vinicius B M Brito; Gilmar F Santos; Thiago D S Silva; Júlia L C Souza; Gardenia C G Militão; Felipe T Martins; Fábio P L Silva; Boaz G Oliveira; Edigenia C C Araújo; Mário L A A Vasconcellos; Claudio G Lima-Júnior; Edilson B Alencar-Filho
Journal:  Mol Divers       Date:  2019-04-06       Impact factor: 2.943

2.  Morita-Baylis-Hillman Adduct 2-(3-Hydroxy-2-oxoindolin-3-yl)acrylonitrile (ISACN) Modulates Inflammatory Process In vitro and In vivo.

Authors:  Juliane Santos de França; José Marreiro de Sales-Neto; Deyse Cristina Madruga Carvalho; Éssia de Almeida Lima; Tayná Rodrigues Olegário; Rhuan Karlos Santos Mendes; Claudio Gabriel Lima-Junior; Mário Luiz Araújo de Almeida Vasconcellos; Sandra Rodrigues-Mascarenhas
Journal:  Inflammation       Date:  2020-11-24       Impact factor: 4.657

3.  Morita-Baylis-Hillman Adducts Display Anti-Inflammatory Effects by Modulating Inflammatory Mediator Expression in RAW264.7 Cells.

Authors:  Glaucia V Faheina-Martins; Jacqueline Alves Leite; Bruna Braga Dantas; Cláudio G Lima-Júnior; Mário L A A Vasconcellos; Sandra Rodrigues-Mascarenhas; Demetrius A M Araújo
Journal:  Mediators Inflamm       Date:  2017-07-12       Impact factor: 4.711

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.